Across 127 studies, CBCT-guided online adaptation repeatedly improved target coverage and OAR sparing, while evidence for better clinical outcomes remained sparse.
Dynamic tangential IMRT delivered left-breast DIBH 42% faster than VMAT with similar target coverage and lower low-dose normal-tissue exposure.
AI-generated synthetic CT achieved 99.8% gamma agreement with conventional CT while automated pelvic contours remained within expert interobserver variability.
No prospective trial has established the safety of combining partial breast irradiation with sentinel lymph node biopsy omission in early breast cancer.
Spatially fractionated radiotherapy relieved symptoms in 91.7% of patients with bulky advanced tumors without reported grade ≥3 toxicity.
Neoadjuvant chemoradiotherapy achieved 26.5% pathological complete response and 80.4% five-year survival, outperforming chemotherapy-based strategies in this retrospective cohort.
Boosting selected proton spots reduced simulated prompt-gamma noise by up to 93.3% while maintaining acceptable target and organ-at-risk dosimetry.
Twelve-month TME-free survival was 78.5% with long-course chemoradiotherapy versus 60.6% with short-course radiotherapy in early rectal cancer.
Across five phase III trials, whole-pelvic radiotherapy did not improve overall survival, and progression benefits disappeared when POP-RT was excluded.
Postoperative proton therapy achieved 84% five-year local control in paediatric ependymoma
Hybrid ultra-high and conventional dose-rate irradiation retained FLASH sparing in mice, but protection diminished as the ultra-high-rate dose contribution decreased.
After surgery and 14 Gy hemithoracic radiotherapy, five-year progression-free survival was 50.8% with only one grade 3 pneumonitis.
Only three in-field solid malignancies occurred among 4,699 patients, while marrow-adjacent irradiation was associated with slightly more hematologic malignancies.
Week-three CBCT dose changes predicted head and neck adaptive radiotherapy benefit with AUC 0.78 versus 0.54 using volume changes.
Five-year PSA progression-free survival was 24.8% after two-fraction salvage HDR brachytherapy without androgen deprivation, despite low severe toxicity.